Research Reports

Key takeaways

Operating loss narrowed 99.3% to -$3.4M from -$520.1M, due to no goodwill impairments this year versus prior period and restructuring benefits including lower personnel costs.

Net loss improved 95.8% to -$23.6M from -$562.9M, reflecting absence of prior-year impairments offset by valuation allowance on interest deductibility limitations.

Diluted EPS improved 96.0% to -$0.25 from -$6.25, tied to reduced impairment impact and operational efficiencies.

Operating cash use improved to -$17.0M from -$124.2M, primarily from higher accounts receivable collections, lower payables usage, and better net income excluding non-cash impairments.

Restructuring actions continue through 2026 to enhance efficiency; no draws on revolving credit facility required.

Full analysis

Net income loss narrowed to $23.6 million from $562.9 million, or 95.8% better, with diluted EPS at -$0.25 versus -$6.25. The effective tax rate fluctuation arose from prior-year goodwill impairment without tax benefit and BEAT exposure, contrasted with this year's valuation allowance tied to expected interest deductibility limits. These adjustments underscore the non-recurring nature of last year's hit and ongoing tax structuring efforts.

Operationally, the backlog incorporates cancellation and adjustment activity, and the company lacks contractual rights to full award amounts, introducing execution risks. Management remains focused on selective investments in key therapeutic areas, business lines, and geographies to drive growth and operational efficiency. Restructuring plans are expected to continue through 2026, positioning Fortrea for improved profitability absent one-time charges while navigating revenue headwinds from FSP and pass-through normalization.

FTRE · Fortrea Holdings Inc.

Summary

Key takeaways

Full analysis